Movement Alert｜EVEREST MED Falls 5.2% in Regular Trading, mRNA Concept Sentiment Cooling and Sector Weakness Trigger Pullback

Market Focus08-28

On August 28, EVEREST MED fell 5.2% in regular trading to HK$34.96, with turnover of HK$325 million. The decline was driven by fading enthusiasm for the mRNA concept and broad weakness across the biotech sector, with sector peer CanSino Bio dropping over 10% on the same day.

The stock had previously rallied sharply following Moderna and Merck's announcement of positive Phase III results for their mRNA personalized cancer vaccine on August 20, which triggered a sector-wide surge. EVEREST MED benefited from its proprietary mRNA platform, including personalized tumor vaccine EVM16 and off-the-shelf vaccine EVM14. However, after substantial gains in recent sessions, profit-taking pressure emerged as sector momentum reversed.

On fundamentals, the company reported H1 revenue of RMB 1.148 billion, up 157% year-over-year, achieving a turnaround to profitability. Core product Nefecon recorded 94% sales growth. BOCOM International maintained a Buy rating with a HK$66 target price but cut revenue forecasts by 15-18%, citing intensifying competition for Nefecon and supply constraints for Xerava.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173600020?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 14:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173600020","market":"hk","top_or_hot":-1,"title":"Movement Alert｜EVEREST MED Falls 5.2% in Regular Trading, mRNA Concept Sentiment Cooling and Sector Weakness Trigger Pullback","media":"Market Focus","content":"<p><p>On August 28, EVEREST MED fell 5.2% in regular trading to HK$34.96, with turnover of HK$325 million. The decline was driven by fading enthusiasm for the mRNA concept and broad weakness across the biotech sector, with sector peer CanSino Bio dropping over 10% on the same day.</p><p>The stock had previously rallied sharply following Moderna and Merck's announcement of positive Phase III results for their mRNA personalized cancer vaccine on August 20, which triggered a sector-wide surge. EVEREST MED benefited from its proprietary mRNA platform, including personalized tumor vaccine EVM16 and off-the-shelf vaccine EVM14. However, after substantial gains in recent sessions, profit-taking pressure emerged as sector momentum reversed.</p><p>On fundamentals, the company reported H1 revenue of RMB 1.148 billion, up 157% year-over-year, achieving a turnaround to profitability. Core product Nefecon recorded 94% sales growth. BOCOM International maintained a Buy rating with a HK$66 target price but cut revenue forecasts by 15-18%, citing intensifying competition for Nefecon and supply constraints for Xerava.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜EVEREST MED Falls 5.2% in Regular Trading, mRNA Concept Sentiment Cooling and Sector Weakness Trigger Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜EVEREST MED Falls 5.2% in Regular Trading, mRNA Concept Sentiment Cooling and Sector Weakness Trigger Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-28 14:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 28, EVEREST MED fell 5.2% in regular trading to HK$34.96, with turnover of HK$325 million. The decline was driven by fading enthusiasm for the mRNA concept and broad weakness across the biotech sector, with sector peer CanSino Bio dropping over 10% on the same day.</p><p>The stock had previously rallied sharply following Moderna and Merck's announcement of positive Phase III results for their mRNA personalized cancer vaccine on August 20, which triggered a sector-wide surge. EVEREST MED benefited from its proprietary mRNA platform, including personalized tumor vaccine EVM16 and off-the-shelf vaccine EVM14. However, after substantial gains in recent sessions, profit-taking pressure emerged as sector momentum reversed.</p><p>On fundamentals, the company reported H1 revenue of RMB 1.148 billion, up 157% year-over-year, achieving a turnaround to profitability. Core product Nefecon recorded 94% sales growth. BOCOM International maintained a Buy rating with a HK$66 target price but cut revenue forecasts by 15-18%, citing intensifying competition for Nefecon and supply constraints for Xerava.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1173600020","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173600020","pubTimestamp":1787900085,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 28, EVEREST MED fell 5.2% in regular trading to HK$34.96, with turnover of HK$325 million. The decline was driven by fading enthusiasm for the mRNA concept and broad weakness across the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀"},"translate_title":"走势警报|珠穆朗玛峰医疗常规交易下跌5.2%，mRNA概念情绪降温，板块疲软引发回调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"On August 28, EVEREST MED fell 5.2% in regular trading to HK$34.96, with turnover of HK$325 million. The decline was driven by fading enthusiasm for the mRNA concept and broad weakness across the biotech sector, with sector peer CanSino Bio dropping over 10% on the same day.The stock had previously rallied sharply following Moderna and Merck's announcement of positive Phase III results for their mRNA personalized cancer vaccine on August 20, which triggered a sector-wide surge. EVEREST MED benefited from its proprietary mRNA platform, including personalized tumor vaccine EVM16 and off-the-shelf vaccine EVM14. However, after substantial gains in recent sessions, profit-taking pressure emerged as sector momentum reversed.On fundamentals, the company reported H1 revenue of RMB 1.148 billion, up 157% year-over-year, achieving a turnaround to profitability. Core product Nefecon recorded 94% sales growth. BOCOM International maintained a Buy rating with a HK$66 target price but cut revenue forecasts by 15-18%, citing intensifying competition for Nefecon and supply constraints for Xerava.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173600020","isCrawlerRequest":true}